InvestorsHub Logo
Followers 78
Posts 11422
Boards Moderated 0
Alias Born 04/03/2014

Re: misiu143 post# 28945

Thursday, 09/20/2018 6:31:24 AM

Thursday, September 20, 2018 6:31:24 AM

Post# of 232337
Nader clearly said that they will need new pivotal - multiple reasons

1. This was not a pivotal trial
2. Dosing was changed from 325 to 550 to 700 mg - this kind of trial does not lock final dosing for approval. This kind of change shows exploration of optimal dosing which is a feature of P2b
3. Seems Nader is not very comfortable efficacy of 525 - he wants to aim high - a 90%+ response rate will seal the deal and give competitive advantage

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News